Chimeric Antigen Receptor (CAR)-T Therapy Market 2028 By Therapeutic Application, Structure, Development Processes, End User and Geography | The Insight Partners

    Chimeric Antigen Receptor (CAR)-T Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Application (Leukemia, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Others); Structure (First Generation CAR-T Cells, Second Generation CAR-T Cells, Third Generation CAR-T Cells, Others); Development Processes (Autologous CAR-T Cells, Allogeneic CAR-T Cells, Others); End User (Hospitals, Homecare, Specialty Clinics, Others) and Geography

    Report Code: TIPRE00028575 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET OVERVIEW
    Chimeric Antigen Receptor (CAR)-T Therapy is a way to get immune cells called T cells that are a type of white blood cell, to fight cancer by changing them in the lab so they can find and destroy cancer cells. Chimeric antigen receptor T cells are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy. Chimeric antigen receptors are receptor proteins that have been engineered to give T cells the new ability to target a specific protein

    MARKET SCOPE
    The "Global Chimeric Antigen Receptor (CAR)-T Therapy Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Chimeric Antigen Receptor (CAR)-T Therapy market with detailed market segmentation by drug class and distribution channel. The report provides key statistics on the market status of the leading Chimeric Antigen Receptor (CAR)-T Therapy market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION

    •   Based on therapeutic application the market is segmented as, leukemia, pancreatic cancer, breast cancer, lung cancer, gastric cancer, and others.
    •   Based on structure the market is segmented as, first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and others
    •   Based on development process the market is segmented as, autologous CAR-T cells, allogenic CAT-T cells, and others
    •   Based on end user the market is segmented as, hospitals, homecare, specialty clinics, and others.

    MARKET DYNAMICS
    Drivers:

    •   Rising prevalence of immunological disorders and increasing volume of patients with active immunological disorders.
    •   Increasing awareness and use of Chimeric Antigen Receptor (CAR)-T Therapy.
    •   Extensive R&D efforts by biotechnological and pharmaceutical companies to develop novel therapies such as Chimeric Antigen Receptor (CAR)-T Therapy is expected to fuel the market growth.

    Restraints:

    •   Long time process for Chimeric Antigen Receptor (CAR)-T Therapy.
    •   Whereas, high cost of Chimeric Antigen Receptor (CAR)-T Therapy is expected to restrain market growth during the forecast period.

    REGIONAL FRAMEWORK
    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America. The Chimeric Antigen Receptor (CAR)-T Therapy market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

    The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South and Central America after evaluating political, economic, social and technological factors affecting the Chimeric Antigen Receptor (CAR)-T Therapy market in these regions.

    IMPACT OF COVID-19 ON CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET
    COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



    Get more information on this report :

    MARKET PLAYERS

    The report covers key developments in the Chimeric Antigen Receptor (CAR)-T Therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Chimeric Antigen Receptor (CAR)-T Therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for Chimeric Antigen Receptor (CAR)-T Therapy in the global market.

    The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Chimeric Antigen Receptor (CAR)-T Therapy market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    •   NOVARTIS AG
    •   GILEAD SCIENCES, INC
    •   ABBVIE INC
    •   ADAPTIMMUNE
    •   AMGEN INC.
    •   ATARA BIOTHERAPEUTICS.
    •   AURORA BIOPHARMA
    •   AUTOLUS
    •   BELLICUM PHARMACEUTICALS, INC
    •   BIOATLA LLC.
    •   BRISTOL-MYERS SQUIBB COMPANY
    •   CARINA BIOTECH
    •   CARSGEN THERAPEUTICS
    •   CARTHERICS PTY LTD, CELLECTIS
    •   ZIOPHARM ONCOLOGY, INC.
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


    Get more information on this report :

    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Chimeric Antigen Receptor (CAR)-T Therapy Market - By Therapeutic Application
    1.3.2 Chimeric Antigen Receptor (CAR)-T Therapy Market - By Structure
    1.3.3 Chimeric Antigen Receptor (CAR)-T Therapy Market - By Development Processes
    1.3.4 Chimeric Antigen Receptor (CAR)-T Therapy Market - By End User
    1.3.5 Chimeric Antigen Receptor (CAR)-T Therapy Market - By Region
    1.3.5.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PEST ANALYSIS
    4.2.1 North America - Pest Analysis
    4.2.2 Europe - Pest Analysis
    4.2.3 Asia-Pacific - Pest Analysis
    4.2.4 Middle East and Africa - Pest Analysis
    4.2.5 South and Central America - Pest Analysis
    4.3. EXPERT OPINIONS

    5. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET - GLOBAL MARKET ANALYSIS
    6.1. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY - GLOBAL MARKET OVERVIEW
    6.2. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING

    7. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC APPLICATION
    7.1. OVERVIEW
    7.2. THERAPEUTIC APPLICATION MARKET FORECASTS AND ANALYSIS
    7.3. LEUKEMIA
    7.3.1. Overview
    7.3.2. Leukemia Market Forecast and Analysis
    7.4. PANCREATIC CANCER
    7.4.1. Overview
    7.4.2. Pancreatic Cancer Market Forecast and Analysis
    7.5. BREAST CANCER
    7.5.1. Overview
    7.5.2. Breast Cancer Market Forecast and Analysis
    7.6. LUNG CANCER
    7.6.1. Overview
    7.6.2. Lung Cancer Market Forecast and Analysis
    7.7. GASTRIC CANCER
    7.7.1. Overview
    7.7.2. Gastric Cancer Market Forecast and Analysis
    7.8. OTHERS
    7.8.1. Overview
    7.8.2. Others Market Forecast and Analysis
    8. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET - REVENUE AND FORECASTS TO 2028 - STRUCTURE
    8.1. OVERVIEW
    8.2. STRUCTURE MARKET FORECASTS AND ANALYSIS
    8.3. FIRST GENERATION CAR-T CELLS
    8.3.1. Overview
    8.3.2. First Generation CAR-T Cells Market Forecast and Analysis
    8.4. SECOND GENERATION CAR-T CELLS
    8.4.1. Overview
    8.4.2. Second Generation CAR-T Cells Market Forecast and Analysis
    8.5. THIRD GENERATION CAR-T CELLS
    8.5.1. Overview
    8.5.2. Third Generation CAR-T Cells Market Forecast and Analysis
    8.6. OTHERS
    8.6.1. Overview
    8.6.2. Others Market Forecast and Analysis
    9. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET - REVENUE AND FORECASTS TO 2028 - DEVELOPMENT PROCESSES
    9.1. OVERVIEW
    9.2. DEVELOPMENT PROCESSES MARKET FORECASTS AND ANALYSIS
    9.3. AUTOLOGOUS CAR-T CELLS
    9.3.1. Overview
    9.3.2. Autologous CAR-T Cells Market Forecast and Analysis
    9.4. ALLOGENEIC CAR-T CELLS
    9.4.1. Overview
    9.4.2. Allogeneic CAR-T Cells Market Forecast and Analysis
    9.5. OTHERS
    9.5.1. Overview
    9.5.2. Others Market Forecast and Analysis
    10. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET - REVENUE AND FORECASTS TO 2028 - END USER
    10.1. OVERVIEW
    10.2. END USER MARKET FORECASTS AND ANALYSIS
    10.3. HOSPITALS
    10.3.1. Overview
    10.3.2. Hospitals Market Forecast and Analysis
    10.4. HOMECARE
    10.4.1. Overview
    10.4.2. Homecare Market Forecast and Analysis
    10.5. SPECIALTY CLINICS
    10.5.1. Overview
    10.5.2. Specialty Clinics Market Forecast and Analysis
    10.6. OTHERS
    10.6.1. Overview
    10.6.2. Others Market Forecast and Analysis

    11. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    11.1. NORTH AMERICA
    11.1.1 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Overview
    11.1.2 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis
    11.1.3 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Therapeutic Application
    11.1.4 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Structure
    11.1.5 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Development Processes
    11.1.6 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By End User
    11.1.7 North America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Countries
    11.1.7.1 United States Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.1.7.1.1 United States Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.1.7.1.2 United States Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.1.7.1.3 United States Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.1.7.1.4 United States Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.1.7.2 Canada Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.1.7.2.1 Canada Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.1.7.2.2 Canada Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.1.7.2.3 Canada Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.1.7.2.4 Canada Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.1.7.3 Mexico Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.1.7.3.1 Mexico Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.1.7.3.2 Mexico Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.1.7.3.3 Mexico Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.1.7.3.4 Mexico Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.2. EUROPE
    11.2.1 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Overview
    11.2.2 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis
    11.2.3 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Therapeutic Application
    11.2.4 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Structure
    11.2.5 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Development Processes
    11.2.6 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By End User
    11.2.7 Europe Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Countries
    11.2.7.1 Germany Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.2.7.1.1 Germany Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.2.7.1.2 Germany Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.2.7.1.3 Germany Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.2.7.1.4 Germany Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.2.7.2 France Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.2.7.2.1 France Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.2.7.2.2 France Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.2.7.2.3 France Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.2.7.2.4 France Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.2.7.3 Italy Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.2.7.3.1 Italy Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.2.7.3.2 Italy Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.2.7.3.3 Italy Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.2.7.3.4 Italy Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.2.7.4 Spain Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.2.7.4.1 Spain Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.2.7.4.2 Spain Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.2.7.4.3 Spain Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.2.7.4.4 Spain Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.2.7.5 United Kingdom Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.2.7.5.1 United Kingdom Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.2.7.5.2 United Kingdom Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.2.7.5.3 United Kingdom Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.2.7.5.4 United Kingdom Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.2.7.6 Rest of Europe Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.2.7.6.1 Rest of Europe Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.2.7.6.2 Rest of Europe Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.2.7.6.3 Rest of Europe Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.2.7.6.4 Rest of Europe Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.3. ASIA-PACIFIC
    11.3.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Overview
    11.3.2 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis
    11.3.3 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Therapeutic Application
    11.3.4 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Structure
    11.3.5 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Development Processes
    11.3.6 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By End User
    11.3.7 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Countries
    11.3.7.1 Australia Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.3.7.1.1 Australia Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.3.7.1.2 Australia Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.3.7.1.3 Australia Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.3.7.1.4 Australia Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.3.7.2 China Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.3.7.2.1 China Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.3.7.2.2 China Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.3.7.2.3 China Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.3.7.2.4 China Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.3.7.3 India Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.3.7.3.1 India Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.3.7.3.2 India Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.3.7.3.3 India Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.3.7.3.4 India Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.3.7.4 Japan Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.3.7.4.1 Japan Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.3.7.4.2 Japan Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.3.7.4.3 Japan Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.3.7.4.4 Japan Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.3.7.5 South Korea Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.3.7.5.1 South Korea Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.3.7.5.2 South Korea Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.3.7.5.3 South Korea Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.3.7.5.4 South Korea Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.3.7.6 Rest of Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.3.7.6.1 Rest of Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.3.7.6.2 Rest of Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.3.7.6.3 Rest of Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.3.7.6.4 Rest of Asia-Pacific Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.4. MIDDLE EAST AND AFRICA
    11.4.1 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Overview
    11.4.2 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis
    11.4.3 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Therapeutic Application
    11.4.4 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Structure
    11.4.5 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Development Processes
    11.4.6 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By End User
    11.4.7 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Countries
    11.4.7.1 South Africa Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.4.7.1.1 South Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.4.7.1.2 South Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.4.7.1.3 South Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.4.7.1.4 South Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.4.7.2 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.4.7.2.1 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.4.7.2.2 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.4.7.2.3 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.4.7.2.4 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.4.7.3 U.A.E Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.4.7.3.1 U.A.E Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.4.7.3.2 U.A.E Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.4.7.3.3 U.A.E Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.4.7.3.4 U.A.E Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.4.7.4 Rest of Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.4.7.4.1 Rest of Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.4.7.4.2 Rest of Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.4.7.4.3 Rest of Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.4.7.4.4 Rest of Middle East and Africa Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.5. SOUTH AND CENTRAL AMERICA
    11.5.1 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Overview
    11.5.2 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis
    11.5.3 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Therapeutic Application
    11.5.4 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Structure
    11.5.5 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Development Processes
    11.5.6 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By End User
    11.5.7 South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market Forecasts and Analysis - By Countries
    11.5.7.1 Brazil Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.5.7.1.1 Brazil Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.5.7.1.2 Brazil Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.5.7.1.3 Brazil Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.5.7.1.4 Brazil Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.5.7.2 Argentina Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.5.7.2.1 Argentina Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.5.7.2.2 Argentina Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.5.7.2.3 Argentina Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.5.7.2.4 Argentina Chimeric Antigen Receptor (CAR)-T Therapy Market by End User
    11.5.7.3 Rest of South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market
    11.5.7.3.1 Rest of South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market by Therapeutic Application
    11.5.7.3.2 Rest of South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market by Structure
    11.5.7.3.3 Rest of South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market by Development Processes
    11.5.7.3.4 Rest of South and Central America Chimeric Antigen Receptor (CAR)-T Therapy Market by End User

    12. INDUSTRY LANDSCAPE
    12.1. MERGERS AND ACQUISITIONS
    12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    12.3. NEW PRODUCT LAUNCHES
    12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    13. CHIMERIC ANTIGEN RECEPTOR (CAR)-T THERAPY MARKET, KEY COMPANY PROFILES
    13.1. NOVARTIS AG
    13.1.1. Key Facts
    13.1.2. Business Description
    13.1.3. Products and Services
    13.1.4. Financial Overview
    13.1.5. SWOT Analysis
    13.1.6. Key Developments
    13.2. GILEAD SCIENCES, INC
    13.2.1. Key Facts
    13.2.2. Business Description
    13.2.3. Products and Services
    13.2.4. Financial Overview
    13.2.5. SWOT Analysis
    13.2.6. Key Developments
    13.3. ABBVIE INC
    13.3.1. Key Facts
    13.3.2. Business Description
    13.3.3. Products and Services
    13.3.4. Financial Overview
    13.3.5. SWOT Analysis
    13.3.6. Key Developments
    13.4. ADAPTIMMUNE
    13.4.1. Key Facts
    13.4.2. Business Description
    13.4.3. Products and Services
    13.4.4. Financial Overview
    13.4.5. SWOT Analysis
    13.4.6. Key Developments
    13.5. AMGEN INC.
    13.5.1. Key Facts
    13.5.2. Business Description
    13.5.3. Products and Services
    13.5.4. Financial Overview
    13.5.5. SWOT Analysis
    13.5.6. Key Developments
    13.6. ATARA BIOTHERAPEUTICS.
    13.6.1. Key Facts
    13.6.2. Business Description
    13.6.3. Products and Services
    13.6.4. Financial Overview
    13.6.5. SWOT Analysis
    13.6.6. Key Developments
    13.7. AURORA BIOPHARMA
    13.7.1. Key Facts
    13.7.2. Business Description
    13.7.3. Products and Services
    13.7.4. Financial Overview
    13.7.5. SWOT Analysis
    13.7.6. Key Developments
    13.8. AUTOLUS
    13.8.1. Key Facts
    13.8.2. Business Description
    13.8.3. Products and Services
    13.8.4. Financial Overview
    13.8.5. SWOT Analysis
    13.8.6. Key Developments
    13.9. BELLICUM PHARMACEUTICALS, INC
    13.9.1. Key Facts
    13.9.2. Business Description
    13.9.3. Products and Services
    13.9.4. Financial Overview
    13.9.5. SWOT Analysis
    13.9.6. Key Developments
    13.10. BIOATLA LLC.
    13.10.1. Key Facts
    13.10.2. Business Description
    13.10.3. Products and Services
    13.10.4. Financial Overview
    13.10.5. SWOT Analysis
    13.10.6. Key Developments
    13.11. BRISTOL-MYERS SQUIBB COMPANY
    13.11.1. Key Facts
    13.11.2. Business Description
    13.11.3. Products and Services
    13.11.4. Financial Overview
    13.11.5. SWOT Analysis
    13.11.6. Key Developments
    13.12. CARINA BIOTECH
    13.12.1. Key Facts
    13.12.2. Business Description
    13.12.3. Products and Services
    13.12.4. Financial Overview
    13.12.5. SWOT Analysis
    13.12.6. Key Developments
    13.13. CARSGEN THERAPEUTICS
    13.13.1. Key Facts
    13.13.2. Business Description
    13.13.3. Products and Services
    13.13.4. Financial Overview
    13.13.5. SWOT Analysis
    13.13.6. Key Developments
    13.14. CARTHERICS PTY LTD, CELLECTIS
    13.14.1. Key Facts
    13.14.2. Business Description
    13.14.3. Products and Services
    13.14.4. Financial Overview
    13.14.5. SWOT Analysis
    13.14.6. Key Developments
    13.15. ZIOPHARM ONCOLOGY, INC.
    13.15.1. Key Facts
    13.15.2. Business Description
    13.15.3. Products and Services
    13.15.4. Financial Overview
    13.15.5. SWOT Analysis
    13.15.6. Key Developments

    14. APPENDIX
    14.1. ABOUT THE INSIGHT PARTNERS
    14.2. GLOSSARY OF TERMS
    The List of Companies

    1.Novartis AG
    2.Gilead Sciences, Inc
    3.AbbVie Inc
    4.Adaptimmune
    5.Amgen Inc.
    6.Atara Biotherapeutics.
    7.Aurora Biopharma
    8.Autolus
    9.Bellicum Pharmaceuticals, Inc
    10.BioAtla LLC.
    11.Bristol-Myers Squibb Company
    12.CARINA BIOTECH
    13.CARsgen Therapeutics
    14.Cartherics Pty ltd, Cellectis
    15.Ziopharm Oncology, Inc.
    TIPRE00028575
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount